ArticleActa diabetologica2026
miR-1180-5p as a potential biomarker for the standard diagnosis of gestational diabetes and its correlation with pregnancy outcomes.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational diabetes mellitus (GDM) poses a serious threat to maternal and fetal health.
objectiveTo investigate the clinical significance and molecular mechanisms of miR-1180-5p in GDM and evaluate its potential as a diagnostic and prognostic biomarker.
methodsIt includes GDM patients and healthy pregnant women in this research. The diagnostic value of miR-1180-5p expression levels for GDM was estimated using ROC curves. Correlation analysis was used to estimate the relationship between miR-1180-5p expression levels and GDM indicators. Multivariate logistic regression analysis was performed to estimate the risks of poor pregnancy outcomes in patients with GDM.
resultsmiR-1180-5p expression was significantly elevated in GDM patients, and the ROC curve indicated it had moderate diagnostic efficacy. Its expression was closely linked to fasting blood glucose and HOMA-IR. The high-expression group showed increased neonatal and placental weights and a higher incidence of adverse pregnancy outcomes. It was confirmed that it can target and combine to the TXLNA to regulate expression.
conclusionmiR-1180-5p is a potential diagnostic and prognostic biomarker for GDM. It participates in the pathological process of GDM through its target regulation mechanism, thus providing new evidence for clinical management.
Indexed as
Identifiers
41843086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.